Zevra Therapeutics Inc (NAS:ZVRA)

$ 9.5 0.07 (0.74%) Market Cap: 507.07 Mil Enterprise Value: 477.62 Mil PE Ratio: 0 PB Ratio: 7.25 GF Score: 45/100

Q3 2024 Zevra Therapeutics Inc Earnings Call Transcript
Nov 12, 2024

$8.57 (-4.35%)

Earnings
Q2 2024 Zevra Therapeutics Inc Earnings Call Transcript
Aug 13, 2024

$6.78 (-0.44%)

Earnings
Q1 2024 Zevra Therapeutics Inc Earnings Call Transcript
May 08, 2024

$5.16 (-0.29%)

Earnings
Q4 2023 Zevra Therapeutics Inc Earnings Call Transcript
Mar 28, 2024

$5.8 (-2.36%)

Earnings
Q3 2023 Zevra Therapeutics Inc Earnings Call Transcript
Nov 07, 2023

$4.4 (-3.51%)

Earnings
Zevra Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 27, 2023
Zevra Therapeutics Inc To Acquire Acer Therapeutics Inc Transcript
Aug 31, 2023
Q2 2023 Zevra Therapeutics Inc Earnings Call Transcript
Aug 14, 2023

$5.4 (+3.85%)

Earnings
Zevra Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023
Q1 2023 Zevra Therapeutics Inc Earnings Call Transcript
May 15, 2023

$4.36 (+3.07%)

Earnings
Q4 2022 Zevra Therapeutics Inc Earnings Call Transcript
Mar 07, 2023

$4.31 (-19.44%)

Earnings
Q3 2022 KemPharm Inc Earnings Call Transcript
Nov 09, 2022

$5.36 (-4.96%)

Earnings
Q2 2022 KemPharm Inc Earnings Call Transcript
Aug 11, 2022

$6.18 (-4.33%)

Earnings
KemPharm Inc Annual Shareholders Meeting Transcript
Jun 28, 2022
KemPharm Inc at JMP Securities Life Sciences Conference (Virtual) Transcript
Jun 15, 2022
KemPharm Inc - Special Call Transcript
May 16, 2022
Q1 2022 KemPharm Inc Earnings Call Transcript
May 12, 2022

$4.24 (+5.47%)

Earnings
Q4 2021 KemPharm Inc Earnings Call Transcript
Mar 30, 2022

$5.32 (+0.76%)

Earnings
KemPharm Inc Pipeline & Clinical Development Update Conference Call Transcript
Jan 19, 2022
Q3 2021 KemPharm Inc Earnings Call Transcript
Nov 10, 2021

$9.1 (-2.88%)

Earnings
Q2 2021 KemPharm Inc Earnings Call Transcript
Aug 12, 2021

$10.19 (+1.49%)

Earnings
Q1 2021 KemPharm Inc Earnings Call Transcript
May 13, 2021

$8.52 (-3.29%)

Earnings
KemPharm Inc to Discuss the Amendments to License Agreement - Conference Call Transcript
Apr 08, 2021
Q4 2020 KemPharm Inc Earnings Call Transcript
Mar 11, 2021

$9.98 (-3.11%)

Earnings
KemPharm, Inc. - Special Call Transcript
Mar 03, 2021
Corium International, Inc., KemPharm, Inc. - Special Call Transcript
Dec 02, 2020
Q3 2020 KemPharm Inc Earnings Call Transcript
Oct 29, 2020

$9.62 (-1.48%)

Earnings
Q2 2020 KemPharm Inc Earnings Call Transcript
Aug 12, 2020

$8.18 (+8.83%)

Earnings
KemPharm Inc Annual Shareholders Meeting Transcript
Jun 19, 2020
Q1 2020 KemPharm Inc Earnings Call Transcript
May 12, 2020

$4.64 (+11.38%)

Earnings
KemPharm, Inc. - Special Call Transcript
Dec 18, 2019
Q3 2019 KemPharm Inc Earnings Call Transcript
Nov 14, 2019

$8.21 (+7.75%)

Earnings
KemPharm, Inc. - Special Call Transcript
Sep 04, 2019
KemPharm, Inc. - Special Call Transcript
Apr 11, 2019
KemPharm, Inc. - Special Call Transcript
Mar 13, 2019
Q4 2018 KemPharm Inc Earnings Call Transcript
Feb 28, 2019

$36 (-8.91%)

Earnings

KemPharm Inc to Discuss the Amendments to License Agreement - Conference Call Transcript

Apr 08, 2021 / 08:30PM GMT

Release Date Price: $10.19 (-1.83%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the KemPharm, Inc. webcast and conference call. (Operator Instructions) I would now like to hand the conference over to your speaker for today, Jason Rando with Tiberend Strategic Advisors. You may begin.

Jason Rando

Tiberend Strategic Advisors, Inc. - COO & EVP

Good afternoon, and thank you for joining today's call to discuss the amendment to the license agreement with an affiliate of Gurnet Point Capital.

Before we begin, I would like to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties and are subject to changes at any time including, but not limited to, statements about KemPharm's expectations regarding future operating results. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations. Actual results may differ materially. KemPharm disclaims any obligation to update or revise its forward-looking

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.